Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

TwongStocks Aug. 26 at 5:21 PM

$APGE Equity Corporate Actions Alert #2026 - 607 Information Regarding the Merger of Apogee Therapeutics, Inc. (APGE) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-607 At a special meeting held on August 11, 2026, the shareholders of Apogee Therapeutics, Inc. (APGE), approved the proposed merger with and into AbbVie Inc. (NYSE: $ABBV ). The merger is tentatively scheduled to close prior to the market open on September 3, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on September 2, 2026. If the merger closes as anticipated, the stock will remain halted on the day of closing (September 3rd) and will be suspended effective September 4, 2026. APGE shareholders will receive $135.11 per share at closing.

0 · Reply

Primeoptionsst Aug. 26 at 5:08 PM

🚨 $ABBV UPDATE 🚨 ABBV is pulling back after getting rejected around the $266 area. But here’s the important part: the company’s fundamentals remain strong. 📊 Q2 revenue: $16.99B (+10.2% YoY) 💰 Adjusted EPS: $3.65 🔥 Skyrizi: +24% 🔥 Rinvoq: +24% ⚠️ Humira: -35.9% AbbVie also raised its 2026 revenue outlook to roughly $67.6B, while slightly lowering EPS guidance because of the Apogee acquisition. For the chart, I’m watching $266–$267.47 as the key upside zone. If ABBV reclaims that area with volume, momentum could strengthen. If it keeps losing support instead, I want to see stabilization before calling a reversal. Strong company ≠ automatic bullish trade. Let price confirm. 📈

0 · Reply

Pas_wayne Aug. 26 at 4:56 PM

$ABBV 28/8 $257.5p @ $1.04 Four-day inside bar + high-confidence downside setup.

0 · Reply

Primeoptionsst Aug. 26 at 4:54 PM

$ABBV 28 AUG 26 $257.5 PUT $1.04

0 · Reply

Snipertradesexpert Aug. 26 at 4:54 PM

$ABBV 28 AUG 26 $257.5 PUT $1.04

0 · Reply

Alphatrades09 Aug. 26 at 4:54 PM

$ABBV 257.5P 8/28 @ 1.04 🦅

0 · Reply

ZacksResearch Aug. 26 at 4:32 PM

$LLY vs. $ABBV — which stock has the stronger growth story? 🔥 Lilly’s 2026 sales and EPS estimates imply 35.4% and 48.4% year-over-year growth, respectively, while AbbVie’s imply 10.5% and 40.6%. 🚀 Lilly: $27.6B from Mounjaro + Zepbound in the first half of 2026 📈 AbbVie: Skyrizi + Rinvoq expected to exceed $31B in 2026 💡 Lilly’s stronger growth trajectory and expanding obesity opportunity make it the better pick. Latest LLY news here 👉 https://www.zacks.com/stock/quote/LLY?cid=sm-stocktwits-0-quote_overview-oc-39386&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39386

0 · Reply

55X_ROI_Q1_2026 Aug. 26 at 3:38 PM

$SLS $MRK $MRNA Gps has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. *Phase 3 Trial Results Imminent. Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. $ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months. SOC: 24.7 --- GPs: > 67.6 Again Note the Key Gps Specific Immune Response. Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 6.7% of the Onureg CR1 Patients Subsequently rec'd transplant.

0 · Reply

Tom2772 Aug. 26 at 2:57 PM

$REGN $ABBV $RHHBY Interesting LYTENAVA Interview This interview is already about a week old, but it’s still very interesting and worth highlighting. A sponsored, retina-focused interview for the U.S. LYTENAVA rollout, aimed less at investors and more at raising awareness within the medical community — especially among retina specialists — ahead of the U.S. launch. Bob Jahr, CEO of Outlook Therapeutics, discusses the FDA approval, LYTENAVA, and its path into retina practice. Dr. Barry Kuppermann, MD, PhD, moderates the interview. He is a practicing retina specialist, Professor and Chair of Ophthalmology & Visual Sciences, as well as Director of the Gavin Herbert Eye Institute at UC Irvine. This puts LYTENAVA directly in front of the medical audience that matters for the U.S. launch. Interesting.. very interesting.. 👀 https://eyetube.net/podcasts/new-retina-radio/the-story-behind-lytenava-from-fda-approval-to-retina-practice

0 · Reply

55X_ROI_Q1_2026 Aug. 26 at 5:31 AM

$SLS $ABBV Is any day now a long time to wait for a 10X to 20X Return on an Investment? We are at the finish Line -and at 5 year High Share Price Waiting for the IMMINENTLY DUE PH3 Results. • 106 Days Since the 78th Event -- while we await 80th -- in a trial where we have truly miraculous survival - for 49 Second Remission CR2 Patients, who are too frail, for transplant. • 60th EVENT Dec 10, 2024 - IDMC UNBLINDED ACTUAL MOS and IR DATA - share price jumped 60% including an offering that doubled the share count - SLS MCAP tripled that week. • 72nd EVENT Dec 26th 2025 - 12 Events in 12 months - its now been 106 - the Share Price Doubled • 78th EVENT May 11, 2206 - 6 Events in 4.5 Months - its now been 106 - the Share Price CRANKED -- Nearly Tripling ... The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA from the INTERIM ANALYSIS that told all the AML players... Gps is Golden - just like ALL Prior Gps trials. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml

0 · Reply

Emily Field: Large pharma companies are going to continue looking at biotech

IBB MRK MRNA XLV

Aug 21, 2026, 7:45 AM EDT - 5 days ago

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

Aug 18, 2026, 8:00 AM EDT - 8 days ago

AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support

Aug 13, 2026, 11:15 PM EDT - 12 days ago

Expert explains why healthcare is a top-performing sector

AMGN BIIB GILD JNJ LLY MRK UNH

Aug 4, 2026, 8:00 AM EDT - 22 days ago

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

Jul 31, 2026, 9:00 AM EDT - 26 days ago

AbbVie Earnings Call Transcript: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 26 days ago

AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 26 days ago

AbbVie Quarterly report: Q2 2026

Jul 31, 2026, 8:36 AM EDT - 26 days ago

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

Jul 31, 2026, 8:31 AM EDT - 26 days ago

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.

Jul 31, 2026, 7:50 AM EDT - 26 days ago

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

Jul 31, 2026, 7:47 AM EDT - 26 days ago

AbbVie Reports Second-Quarter 2026 Financial Results

Jul 30, 2026, 8:00 AM EDT - 27 days ago

JUVÉDERM® Day Returns to U.S. on August 19

Jul 29, 2026, 3:00 AM EDT - 4 weeks ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jul 29, 2026, 3:00 AM EDT - 4 weeks ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

$Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)$

Jul 23, 2026, 4:00 PM EDT - 4 weeks ago

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

GMAB

Jul 17, 2026, 8:00 AM EDT - 5 weeks ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jul 14, 2026, 8:05 AM EDT - 6 weeks ago

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Jul 13, 2026, 5:06 PM EDT - 6 weeks ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

APGE SBIO

Jul 7, 2026, 11:45 AM EDT - 7 weeks ago

Buy these quality, low-stress stocks for the summer, says Jefferies

AXP HD LOW MCD NFLX PEP PG

$AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma$

Jul 6, 2026, 1:45 PM EDT - 7 weeks ago

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Jun 30, 2026, 6:02 AM EDT - 2 months ago

US House committee opens investigation into Merck, AbbVie China drug trials

MRK

$AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma$

Jun 29, 2026, 4:15 PM EDT - 2 months ago

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jun 29, 2026, 3:10 AM EDT - 2 months ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:00 AM EDT - 2 months ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

Jun 26, 2026, 4:50 PM EDT - 2 months ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 2:39 PM EDT - 2 months ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

Jun 26, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 24, 2026, 12:51 PM EDT - 2 months ago

AbbVie's $11 Billion Immunology Bet

APGE

Jun 24, 2026, 8:00 AM EDT - 2 months ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Jun 23, 2026, 8:00 AM EDT - 2 months ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jun 23, 2026, 5:00 AM EDT - 2 months ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 3:00 AM EDT - 2 months ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Jun 22, 2026, 10:30 AM EDT - 2 months ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

Jun 22, 2026, 10:15 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Press release: M&A announcement

Jun 22, 2026, 7:42 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

Jun 22, 2026, 7:06 AM EDT - 2 months ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

Jun 22, 2026, 7:04 AM EDT - 2 months ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

Jun 22, 2026, 7:00 AM EDT - 2 months ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

Jun 20, 2026, 12:11 PM EDT - 2 months ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

Jun 19, 2026, 11:17 AM EDT - 2 months ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

Jun 18, 2026, 4:05 PM EDT - 2 months ago

AbbVie Declares Quarterly Dividend

Jun 16, 2026, 8:00 AM EDT - 2 months ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 12, 2026, 3:00 AM EDT - 2 months ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 10, 2026, 11:47 AM EDT - 2 months ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 9, 2026, 10:40 AM EDT - 2 months ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 2 months ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 3, 2026, 7:04 PM EDT - 2 months ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 3:30 AM EDT - 3 months ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

Jun 2, 2026, 8:00 AM EDT - 3 months ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 29, 2026, 8:00 AM EDT - 3 months ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 27, 2026, 6:18 PM EDT - 3 months ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

TwongStocks Aug. 26 at 5:21 PM

0 · Reply

Primeoptionsst Aug. 26 at 5:08 PM

0 · Reply

Pas_wayne Aug. 26 at 4:56 PM

$ABBV 28/8 $257.5p @ $1.04 Four-day inside bar + high-confidence downside setup.

0 · Reply

Primeoptionsst Aug. 26 at 4:54 PM

$ABBV 28 AUG 26 $257.5 PUT $1.04

0 · Reply

Snipertradesexpert Aug. 26 at 4:54 PM

$ABBV 28 AUG 26 $257.5 PUT $1.04

0 · Reply

Alphatrades09 Aug. 26 at 4:54 PM

$ABBV 257.5P 8/28 @ 1.04 🦅

0 · Reply

ZacksResearch Aug. 26 at 4:32 PM

0 · Reply

55X_ROI_Q1_2026 Aug. 26 at 3:38 PM

0 · Reply

Tom2772 Aug. 26 at 2:57 PM

0 · Reply

55X_ROI_Q1_2026 Aug. 26 at 5:31 AM

0 · Reply

55X_ROI_Q1_2026 Aug. 26 at 4:45 AM

$SLS $ABBV Positive P3 result is coming, any day now, and it'll give Gps the fda greenlight to treat 50,000 Aml remission patients each year and generate $20B a year in real revenue. That is worth a f ton more than the current short rigged $2.89B market cap. Is any Day Now a long time to wait for a 10X to 20X Return on an Investment?

0 · Reply

55X_ROI_Q1_2026 Aug. 26 at 2:20 AM

$SLS $MRK SLS is the Next$MRNA P3 Results Imminent The Gps +Keytruda Phase 2 Combination Trial Data - GPS WT1 Targeted Cancer Vaccine - now in nearly Complete Phase 3 Trial for AML Remission Maintenance is the Closest thing there is to the MRNA Keytruda Trial. Gps has proven Effective in preventing Relapse and Extending Survival 2x 4x in all Prior Trials • Including 2 Phase 2's for AML Remission Maintenance, the Phase 3 Trial Setting. 128 Patients Randomized to BAT - Best Available Treatment or Gps Immunotherapy. Aza+VEN is the BAT for Control ARM Patients, and it Recently Failed 3 Phase 3 Trials conducted by $ABBV - Including Failing the VIALE-M P3 for AML First Remission Maintenance and Failing the VIALE-T Post Transplant Maintenance Trial.

0 · Reply

55X_ROI_Q1_2026 Aug. 26 at 2:04 AM

$SLS Gps Phase 1/2 Combination Results w Keytruda $MRK - MOS of 18.4 months for End Stage Refractory, Platinum Resistant Ovarian Cancer Patients. • MOS 18.4 Months / Longer than $IMGN Elahere 16.4 month MOS in the same Exact Setting (- except 50% were refractory / 75% in Gps P2). $ABBV Paid $10B to buy Elahere $IMGN - and GPS PH2 trial results are better. ... https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won $SLS is the Next $MRNA ---

2 · Reply

55X_ROI_Q1_2026 Aug. 26 at 12:00 AM

$SLS $ABBV $SLS $ABBV $MRNA Is any day now a long time to wait for a 10X to 20X Return on an Investment? We are at the finish Line -and at 5 year High Share Price Waiting for the IMMINENTLY DUE PH3 Results. • 106 Days Since the 78th Event -- while we await 80th -- in a trial where we have truly miraculous survival - for 49 Second Remission CR2 Patients, who are too frail, for transplant. • 60th EVENT Dec 10, 2024 - IDMC UNBLINDED ACTUAL MOS and IR DATA - share price jumped 60% including an offering that doubled the share count - SLS MCAP tripled that week. • 72nd EVENT Dec 26th 2025 - 12 Events in 12 months - its now been 106 - the Share Price Doubled • 78th EVENT May 11, 2206 - 6 Events in 4.5 Months - its now been 106 - the Share Price CRANKED -- Nearly Tripling ... The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA from the INTERIM ANALYSIS that told all the AML players... Gps is Golden - just like all the Prior trials. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml

0 · Reply

55X_ROI_Q1_2026 Aug. 25 at 9:36 PM

$SLS 28 Weeks of Survival w BAT vs 28 Months of Survival for GPs Immune Responders ... in end stage Mesothelioma. -- Immune response is correlated with Extended Survival in all GPs Trials - IDMC UNBLINDED P3 Interim Data: Gps Elicted Immune Response in 80% of Tested Patients.... Gps has proven effective preventing relapse and extending survival in all 7 prior Trials. - Including 2 Phase 2 Trials for AML remission maintenance ... and while we are seeing Miraculous Survival in this Imminently Finished P3... -- Aza+VEN the BAT for Control Arm Patients - Recently FAILED 3 Large Phase 3 Trials Conducted by $ABBV - including Failing 2 P3's for AML Maintenance - VIALE-M and VIALE-T FAILED. - 10 15x Bagger ANY DAY NOW

0 · Reply

Beamen216 Aug. 25 at 7:31 PM

$ABBV its struggling with that 267 mark. Maybe a quick trip to the 250s and we'll try again in a month or so

0 · Reply

DidYouReadThis Aug. 25 at 7:09 PM

Do you think $OTLK #buyers or #sellers are more likely to know which drug in the wet AMD space has had the greatest number of total patients over the last 20 years? #Congrats to #Outlook #Therapeutics on #FDA #Approval! $REGN $ABBV $NVS

0 · Reply

55X_ROI_Q1_2026 Aug. 25 at 6:46 PM

$SLS Gps is worth At LEAST $10B $49.50 per SLS Share Just for Ovarian Cancer Remission Maintenance ala $MRNA adding $40B for Melanoma Remission Maintenance. Gps has proven successful in ALL prior Trials, including 2 for AML Remission Maintenance as well as this Gps Phase 1/2 Combination Results w $MRK Keytruda - MOS of 18.4 months for Endstage Refractory, Platinum Resistant Ovarian Cancer Patients. MOS 18.4 Months / Longer than Elahere 16.4 month MOS in the same Exact Setting - except 50% were refractory / 75% w Gps. $ABBV Paid $10B to buy Elahere $IMGN - and GPS PH2 trial results are better. ... https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won

0 · Reply

55X_ROI_Q1_2026 Aug. 25 at 6:28 PM

$SLS $ABBV We are at the finish Line. • 106 Days Since the 78th Event -- while we await 80 -- in a trial where we are AGAIN - like in ALL Prior GPS Trials - Seeing Truly Miraculous survival - for 49 CR2 - Second Remission Patients, who continue to Survive at Least 30 months, too frail, for Transplant, only a 8 month LE. • 60th EVENT Dec 10, 2024 - IDMC UNBLINDED ACTUAL MOS and IR DATA - share price jumped 60% including an offering that doubled the share count - SLS MCAP tripled that week. • 72nd EVENT Dec 26th 2025 - 12 Events in 12 months - its now been 106 - the Share Price Doubled • 78th EVENT May 11, 2206 - 6 Events in 4.5 Months - its now been 106 - again the Share Price CRANKED -- Nearly Tripling ... The IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA from the INTERIM ANALYSIS that told all the AML players...

0 · Reply

55X_ROI_Q1_2026 Aug. 25 at 6:18 PM

$SLS Of course, Gps Phase 1/2 Combination Results w Keytruda - MOS of 18.4 months for Endstage Refractory, Platinum Resistant Ovarian Cancer Patients. MOS 18.4 Months / Longer than Elahere 16.4 month MOS in the same Exact Setting - except 50% were refractory / 75% w Gps. $ABBV Paid $10B to buy Elahere $IMGN - and GPS PH2 trial results are better. ... https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won $SLS is the Next $MRNA ---

2 · Reply

NotHopeJustFacts Aug. 25 at 6:09 PM

$QTTB keep crying cause this molecule doesn't even match an already approved Rinvoq, why invest on an inferior product ? buy instead $ABBV if you care so much about Bold people, obviously is a stock for grown ups not a penny one

0 · Reply

DidYouReadThis Aug. 25 at 5:43 PM

$ABBV YTD 12/31/26 predictions to be closest to?

0 · Reply

Market Cap	468.13B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	24.38
Forward PE	18.85
Profit Margin	6.91%
Debt to Equity Ratio	-12.03

Volume	1,363,868
Avg Vol	6,974,502
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	94%
Beta	0.30
Analysts	Strong Sell
Price Target	$276.37